Boston Scientific Corp. (BSX) showed an overall strong performance despite minor day-to-day losses, consistently outperforming its competitors. Mixed fundamentals currently do not seem to harm BSX's share price momentum. The company has recently broadened its shareholder base, with D.A. Davidson & CO. Purchasing BSX shares. The company's stocks have been rising, as they beat Q1 Earnings and Revenues, with high expectations for Q1 2024. The addition of Dr. Cheryl Pegus to the Board of Directors has been welcomed. Acquisitions such as Axonics, Inc. and Relievant Medsystems, Inc. are promising moves for the company's development. However, continued share sales by senior officers like EVP Wendy Carruthers raise some concerns. Their stock reached a 52-week high, helped by new products and buyouts, and lifted its 2024 profit forecast due to strong growth from cardiovascular devices. The mCRM system outcome was also reported to be favorable. Despite rising competition and costs, Wall Street remains optimistic about BSX. Additional FDA approval for the AGENT™ Drug-Coated Balloon adds to the positive trend.
Boston Scientific Corp BSX News Analytics from Thu, 27 Jul 2023 07:00:00 GMT to Thu, 30 May 2024 14:02:35 GMT -
Rating 7
- Innovation 7
- Information 8
- Rumor 4
